Doesn't the timing seem short? A well run company and well funded company would have plans in place for a "sudden departure". Press release verbiage covering the issue "During the interim period, the finance and accounting functions will report directly to Sarepta’s Chief Executive Officer, Doug Ingram, and other departments reporting to Mr. Mahatme will be overseen by members of Sarepta’s executive committee.
In any regard he gets accelerated vesting in options. According to the recent Def-14 he has 234,277 stock/options.
From the press release"
"Said Mr. Mahatme, “It has been a privilege to serve as Sarepta’s CFO and CBO for almost eight years and to have participated in its remarkable transformation and extraordinary growth. Working with this leadership team and our talented colleagues, we have built a strong foundation for Sarepta’s ongoing success in achieving its goal of changing the lives of patients with rare diseases around the world. Having built a strong team of finance, IT, facilities, manufacturing and business development professionals, I feel confident that this is a good time to transition to other opportunities, knowing that Sarepta is well-positioned to continue to lead the industry.”
Sandy will continue to serve on the Board of Directors for Flexion Therapeutics, Inc., Aeglea BioTherapeutics, Inc., and Idorsia Pharmaceuticals Ltd."